deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00667953

Study of Temzolomide and Gleevec in Advanced Melanoma

Phase I/II Study of Temozolomide and Gleevec (Imatinib Mesylate, Formerly Known as STI571) in Advanced Melanoma

Sponsor: Abramson Cancer Center at Penn Medicine

Conditions Advanced Melanoma Melanoma
Interventions Gleevec Temodar
Updated 10 times since 2017 Last updated: Mar 7, 2023 Started: Jan 31, 2003 Primary completion: Mar 9, 2011 Completion: Mar 9, 2011
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Difficulty enrolling subjects

Other terminated trials from Abramson Cancer Center at Penn Medicine

See all terminations from Abramson Cancer Center at Penn Medicine

Other Advanced Melanoma trials with similar outcome

Browse all Advanced Melanoma trials

This PHASE1/PHASE2 trial investigates Advanced Melanoma and Melanoma and is currently terminated or withdrawn. Abramson Cancer Center at Penn Medicine leads this study, which shows 10 recorded versions since 2003 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotActive Not Recruiting~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshotActive Not Recruiting~Sep 2018 – ~May 2020 · 20 months · monthly snapshotCompleted~May 2020 – ~Jan 2021 · 8 months · monthly snapshotTerminated~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshotTerminated~Apr 2022 – ~Apr 2023 · 12 months · monthly snapshotTerminated~Apr 2023 – ~Jul 2024 · 15 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 21 months · monthly snapshotTerminated

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Apr 2023 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  4. Apr 2022 — Apr 2023 [monthly]

    Terminated PHASE1_PHASE2

  5. Jan 2021 — Apr 2022 [monthly]

    Terminated PHASE1_PHASE2

▶ Show 5 earlier versions

  1. May 2020 — Jan 2021 [monthly]

    Terminated PHASE1_PHASE2

    Status: Completed → Terminated

  2. Sep 2018 — May 2020 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  3. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Feb 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    First recorded

Jan 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Abramson Cancer Center at Penn Medicine
  • Novartis Pharmaceuticals
Data source: Abramson Cancer Center at Penn Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations